- Home
- BCRX vs MBLY Comparison
BCRX vs MBLY Comparison
Compare BCRX & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCRX | MBLY |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 1995 | 2022 |
Fundamental Metrics
Financial Performance| Metric | BCRX | MBLY |
|---|---|---|
| Price | $9.53 | $8.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 20 |
| Target Price | ★ $20.82 | $14.13 |
| AVG Volume (30 Days) | 4.2M | ★ 8.8M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 381.40 | 87.43 |
| EPS | ★ N/A | N/A |
| Revenue | $25,186,000.00 | ★ $1,894,000,000.00 |
| Revenue This Year | N/A | $4.91 |
| Revenue Next Year | $12.55 | $13.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 14.51 |
| 52 Week Low | $6.00 | $6.47 |
| 52 Week High | $11.22 | $15.81 |
Technical Indicators
Market Signals| Indicator | BCRX | MBLY |
|---|---|---|
| Relative Strength Index (RSI) | 50.19 | 41.65 |
| Support Level | $8.80 | $7.66 |
| Resistance Level | $9.90 | $8.13 |
| Average True Range (ATR) | 0.36 | 0.59 |
| MACD | -0.05 | -0.13 |
| Stochastic Oscillator | 34.75 | 29.36 |
Price Performance
Historical ComparisonAbout BCRX BioCryst Pharmaceuticals Inc.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Moovit. The solutions provided by the company are: Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.